Product Description
Cantharidin is natural toxin produced by the blistering beetle. It has both vesicant and keratolytic features by inducing acanthloysis through targeting the desmosomal dense plaque, leading to detachment of the desmosomes from the tonofilaments. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27319954/)
Mechanisms of Action: PP1 Inhibitor, PP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Egypt | United Kingdom
Approved Indications: None
Company: Verrica
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Molluscum Contagiosum|Papilloma|Warts
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2031230204 |
jRCT2031230204 | P1 |
Recruiting |
Molluscum Contagiosum |
2024-05-31 |
|||
NCT07246590 |
COVE-2 | P3 |
Recruiting |
Papilloma|Warts |
2027-06-01 |
11% |
2026-01-22 |
Primary Endpoints|Start Date|Treatments|Trial Status |
jRCT2031250704 |
jRCT2031250704 | P3 |
Not yet recruiting |
Warts |
2028-07-31 |
|||
NCT07457918 |
COVE-4 | P3 |
Recruiting |
Papilloma|Warts |
2028-04-30 |
6% |
2026-05-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
jRCT2031250703 |
jRCT2031250703 | P3 |
Not yet recruiting |
Warts |
2027-09-30 |
|||
jRCT2041220039 |
jRCT2041220039 | P3 |
Active, not recruiting |
Molluscum Contagiosum |
2024-02-29 |